Description
Research overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist discussed in incretin-pathway literature. This INPEP listing is limited to research context, receptor biology, and qualified handling; it does not provide medical use or compounding guidance.
Research applications
- Dual incretin receptor co-agonism studies involving GIPR and GLP-1R.
- cAMP signaling, receptor-binding, and pathway-response research models.
- Comparative analysis against GLP-1-only and triple-agonist research peptides.
Catalog benefits
- 5mg lyophilized vial format with corrected spelling and clear amount display.
- Unsupported weight-loss language removed and replaced with research-use copy.
- Positioned with caution around FDA concerns regarding unapproved GLP-1 products.
Research-use notice: This product is not intended to diagnose, treat, cure, or prevent disease and is not for human or animal consumption.
Reviews
There are no reviews yet.